Evaluation of National Comprehensive Cancer Network guideline‐based Tool for Risk Assessment for breast and ovarian Cancer (N‐TRAC): A patient‐reported survey for genetic high‐risk assessment for breast and ovarian cancers in women

Abstract

Identification of mutations that increase lifetime risk of breast and ovarian cancer is critical to improving women's health. Because these mutations are relatively rare in the general population, there is a need for efficient methods to identify appropriate women to undergo genetic testing. The objective of this study was to assess the feasibility, accuracy, and performance of the NCCN guideline‐based Tool for Risk Assessment for breast and ovarian Cancer (N‐TRAC)—a patient‐facing assessment for those affected and unaffected by cancer. This study enrolled a prospective cohort of 100 affected and 100 unaffected women that used N‐TRAC in a clinical setting. Recommendations for referral to genetic counseling based on N‐TRAC and other standard risk assessment methods were compared.Seventy‐seven of the 100 affected women and 35 of the 100 unaffected women were identified as high risk by N‐TRAC. The average completion time was approximately 2 min for both groups. N‐TRAC accuracy for family history was exceptional in both groups (kappa > 0.96). N‐TRAC and other risk assessment methods do not always identify the same high risk population. N‐TRAC is an accurate and feasible tool that can assist in identifying women at increased risk for hereditary breast and ovarian cancer and may lead to more informed decision‐making.

Single-cell RNA sequencing reveals osteosarcoma microenvironment differences between chemotherapy and without chemotherapy

“…Detection of TRBC1 expression levels in T-cell lymphomas can rapidly and e ciently diagnose mature T-cell lymphomas and has good clinical application value [46]. TRAC is a favorable prognostic marker in endometrial, cervical, renal, and breast cancers in targeted therapy [47,48]. The results of these genes are consistent with our ndings in the chemotherapy group.…”

A systematic review and quality analysis of cancer pain guidelines

“…[ 16 17 18 ] Some tools were meant for guideline adoption and adaptation in a clinical setting rather than quality assessment [ADAPTED ADAPTE; Rapid Guideline Development (RAPADAPTE); and Adoption, Adaptation, and De novo Development (GRADE ADOLOPMENT)]. [ 19 20 21 22 ] Few established guideline groups had their innate quality evaluation assessment system [National Comprehensive Cancer Network (NCCN guideline-based tool)] and did not incorporate dedicated external quality methods[ 23 ][ Table 1 ].…”

Supplemental Cancer Screening for Women With Dense Breasts: Guidance for Health Care Professionals

“…[138][139][140][141][142][143][144][145][146][147][148][149][150][151] Women at high risk should be encouraged to undergo annual supplemental breast MRI screening in addition to regular annual screening mammography either together or in 6-month intervals, irrespective of breast density. 116,152 A few models include modifiable lifestyle risk factors, such as alcohol intake, body mass index, hormone therapy, 141,153,154 and exercise, that improve the breast cancer risk predictive capability. Risk assessment tools do not always identify the same atrisk groups, and because they use different risk factors that are weighted differently, they can give different risk estimates for the same woman.…”

“…Risk assessment tools do not always identify the same atrisk groups, and because they use different risk factors that are weighted differently, they can give different risk estimates for the same woman. 154 Risks are usually predicted for 5 years, 10 years, or lifetime.…”